Chemomab jumps as FDA accepts application for rare disease therapy trial

Chemomab Therapeutics

02/12/2021 12:45

** Shares of drugmaker Chemomab Therapeutics  CMMB.O  up
~16% at $9.80 premarket
    ** U.S. FDA accepts co's application to begin human trials
for its drug candidate, CM-101, for the treatment of primary
sclerosing cholangitis (PSC)  urn:newsml:reuters.com:*:nPn24Mj2Ka
    ** PSC affects ducts which carry the digestive liquid bile
from liver to the small intestine 
    ** A mid-stage study of CM-101 as a potential treatment for
PSC is already underway in Europe and Israel
    ** Initial data from the study is expected next year 
    ** Up to Wednesday's close, stock had fallen 69.54% YTD 

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))